e-learning
resources
European Respiratory Review
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
Andrew M. Courtwright, Hilary J. Goldberg, Elizabeth Petri Henske, Souheil El-Chemaly
Source:
Eur Respir Rev 2017; 26: 160004
Journal Issue:
January
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Andrew M. Courtwright, Hilary J. Goldberg, Elizabeth Petri Henske, Souheil El-Chemaly. The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis. Eur Respir Rev 2017; 26: 160004
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Lymphangioleiomyomatosis (LAM)
Rare interstitial lung diseases (LAM, LHC, alveolar proteinosis, eosinophilic pneumonias)
The large airway lesions of lymphangioleiomyomatosis: Pathological and radiological analysis
Related content which might interest you:
Effectiveness of inhibitor mTOR in patients with lymphangioleiomyomatosis.
Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children
Year: 2018
Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011
Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells
Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Year: 2018
The therapeutic potential of a new phosphodiesterase inhibitor in acute respiratory distress syndrome
Source: Eur Respir J 2002; 20: Suppl. 38, 36s
Year: 2002
ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis?
Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases
Year: 2012
Preventive and therapeutic effects of phosphoinositide 3-kinase inhibitors on acute lung injury
Source: Annual Congress 2011 - Anti-inflammatory strategies in acute lung injury
Year: 2011
Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders
Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020
Year: 2020
JAK inhibitors overcome corticosteroid insensitivity in COPD
Source: Annual Congress 2011 - COPD: clinical studies and animal cell models
Year: 2011
The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury
Source: Eur Respir J 2003; 22: 20-27
Year: 2003
Targeting the mTOR signaling pathway to inhibit lung cell senescence in chronic obstructive pulmonary disease (COPD)
Source: ERS Lung Science Conference 2017
Year: 2017
The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020
Year: 2020
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice
Source: International Congress 2019 – Novel targets and mechanisms in asthma
Year: 2019
Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Management of pulmonary toxicity associated with immune checkpoint inhibitors
Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019
Year: 2019
Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation
Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept